Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
EVT:ETR
Evotec SE
€5,48
+4,68%
(+0,25) 1D
4 Mei, 11:20:46 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EVT...
Open
€5,38
High
€5,56
Low
€5,38
Mkt. cap
975,66 m
Avg. vol.
804,31 k
Volume
299,68 k
52-wk high
€8,57
52-wk low
€4,00
EPS
-€0,58
Shares outstanding
177,88 m
No. of employees
4 k
News stories
From sources across the web
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4,47 k
Founded1993
Headquarters-
SectorHealth care
Websiteevotec.com
Last report
08 Apr. 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-/ -EUR
Revenue / Estimate
253,27 m/ (265,56 m est.)EUR
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
199,98 m
171,24 m
163,89 m
253,27 m
Cost of goods sold
172,75 m
162,64 m
163,95 m
174,81 m
Cost of revenue
172,75 m
162,64 m
163,95 m
174,81 m
Research and development expenses
10,76 m
8,21 m
8,71 m
9,83 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
47,70 m
41,61 m
42,31 m
44,35 m
Operating expense
47,04 m
37,19 m
43,53 m
55,25 m
Total operating expenses
219,79 m
199,83 m
207,48 m
230,06 m
Operating income
-19,82 m
-28,60 m
-43,59 m
23,21 m
Other non operating income
-6,86 m
-10,64 m
1,19 m
-33,96 m
EBT including unusual items
-29,85 m
-43,42 m
-42,96 m
29,46 m
EBT excluding unusual items
-29,66 m
-44,67 m
-43,36 m
18,35 m
Income tax expense
1,73 m
59,00 k
127,00 k
14,84 m
Effective tax rate
-5,78%
-0,14%
-0,30%
50,37%
Other operating expenses
-11,41 m
-12,63 m
-7,50 m
1,07 m
Net income
-31,58 m
-43,48 m
-43,09 m
14,62 m
Net profit margin
-15,79%
-25,39%
-26,29%
5,77%
Earnings per share
-
-
-0,24
-
Interest and investment income
-
1,21 m
841,00 k
11,84 m
Interest expense
-2,41 m
-6,00 m
-2,28 m
-
Net interest expenses
-2,41 m
-4,79 m
-1,44 m
11,84 m
Depreciation and amortization charges
-
-
-
-
EBITDA
76,50 k
-3,42 m
-18,27 m
41,91 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer